Study: Semaglutide tied to 26% lower predicted 5-year dementia risk

A study published in an Alzheimer’s & Dementia diagnostic journal reports an association between semaglutide (the GLP-1 receptor agonist sold as Ozempic and Wegovy) and a 26% reduction in predicted five-year dementia risk. Note that the finding is framed as a predicted risk reduction, which typically signals a risk-model or observational estimate rather than a randomized outcome — an important distinction the headline alone does not resolve.